Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EP31670
- Development stage
- Phase 1
- Lead developer
- Epigenetix
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
EP31670 (also known as NEO2734) is an orally bioavailable, first-in-class small molecule that acts as a dual inhibitor of the bromodomains of the BET (bromodomain and extra-terminal) family proteins and the histone acetyltransferase paralogs CREB binding protein (CBP) and p300. By targeting both epigenetic "readers" (BET proteins) and "writers" (CBP/p300), EP31670 disrupts oncogenic transcriptional programs critical for cancer cell survival. Preclinical studies have demonstrated potent antitumor activity in hematologic malignancies such as lymphomas, leukemias, myelofibrosis, as well as in solid tumors including prostate cancer and NUT midline carcinoma. The drug is currently being evaluated in Phase 1 clinical trials for advanced solid tumors and hematological malignancies[1][2][3][4][5][7][8].
- Other names
- NEO2734NEO-2734NEO 2734
02
Targets
BRD4 (Bromodomain-containing protein 4)CREBBP BD (Creb-binding protein bromodomain)CREBBP (CREB-binding protein)EP300 (Histone acetyltransferase p300)
Beyond the preview
Go deeper on EP31670.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EP31670.